Table. Characteristics of study isolates with reduced vancomycin susceptibilitya.
| Genotype |
Clonal type | agr type | Vancomycin resistance phenotype (no. of strains) | PAP-AUC | Country of origin | Antimicrobial susceptibility*† |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | ST | SCCmec | Lzd | Syn | Gen | Cip | Rif | |||||
| 5 |
5 |
I |
EMRSA-3 |
II |
hVISA (1) |
0.98 |
UK |
S |
S |
R |
R |
R |
| I |
VISA (1) |
1.9 |
USA |
S |
S |
R |
R |
S |
||||
| 5 |
5 |
II |
New York/Japanese |
II |
hVISA (10) |
0.97–1.23 |
Japan, Sweden, France, Poland, UK, USA, Norway |
S |
S |
S/R |
S/R |
S/R |
| I or II |
VISA (3) |
1.4–1.92 |
USA |
S |
S |
S |
R |
S/R |
||||
| 5 |
5 |
IV |
Pediatric |
I or II |
hVISA (3) |
1.19–1.32 |
UK |
S |
S |
S |
S/R |
S/R |
| 5 |
5 |
NT |
|
I |
VISA (1) |
1.44 |
France |
S |
S |
R |
R |
R |
| 8 |
8 |
I |
|
II |
hVISA (3) |
0.92–1.32 |
France, UK, Norway |
S |
S |
R |
R |
R |
| 8 |
8 |
II |
Irish-1 |
II |
hVISA (3) |
1.04–1.2 |
France, USA, Norway |
S |
S |
S/R |
R |
S/R |
| 8 |
8 |
IV |
EMRSA-4, -6 |
I |
hVISA(11) |
0.94–1.24 |
France, USA |
S |
S/R |
S/R |
R |
S/R |
| 22 |
22 |
IV |
EMRSA-15 |
I or II |
hVISA (7) |
0.9–1.25 |
UK |
S |
S |
S |
R |
S/R |
| 25 |
25 |
NT |
|
I |
hVISA(1) |
1.13 |
UK |
S |
S |
R |
R |
R |
| 30 |
36 |
II |
EMRSA-16 |
II |
hVISA (3) |
0.92–1.17 |
UK |
S |
S |
R |
R |
R |
| 45 |
45 |
II |
|
I |
hVISA (1) |
1 |
USA |
S |
S |
R |
R |
S |
| 8 |
239 |
I or II |
Brazilian/Portuguese |
I or II |
hVISA (10) |
0.9–1.22 |
France, Poland, China, Norway, UK |
S |
S |
R |
S/R |
S/R |
| I |
VISA (3) |
1.44–3.01 |
France, Poland, UK |
S |
S/R |
R |
R |
S/R |
||||
| 8 |
239 |
NT |
|
I |
hVISA (1) |
0.92 |
France |
S |
S |
R |
R |
R |
| 8 |
246 |
NT |
|
I |
hVISA (1) |
1.13 |
Norway |
S |
S |
R |
R |
R |
| 8 | 247 | I | Iberian | I |
VISA (1) |
1.57 |
UK |
S |
S |
R |
R |
R |
| I or II | hVISA (37) | 0.9–1.33 | France, Poland, UK, Norway | S | S | R | R | S/R | ||||
aS, susceptible; R, resistant; NT, nontypeable; PAP-AUC, population analysis profiling followed by measuring the area under the curve; Lzd, linezolid; Syn, synercid; Gen, gentamicin; Cip, ciprofloxacin; Rif, rifampin; CC, clonal complex; ST, sequence type; EMRSA, methicillin-resistant Staphylococcus aureas found in the United Kingdom (UK) ; hVISA, heterogeneous vancomycin-intermediate S. aureus; USA, United States of America.